The Department for Health and Social Care has asked NICE to conduct an appraisal of Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma.
For information, this appraisal has been rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from NICE’s reporting targets for timeliness. In addition, as the delay will mean a NICE recommendation will not be available at the point of marketing authorisation, the company accepts that this drug will consequently not be eligible to receive interim CDF funding from the date of marketing authorisation as no NICE recommendation will be made at that point. For information, this appraisal is now anticipated to begin during mid-May 2021 when we will write to you about how you can get involved.